主要文件

查看所有文档

Y0000198

环丙沙星

Name: 环丙沙星
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

1-环丙基-6-氟-4-氧代-7(1-哌嗪基)-1,4-二氢喹啉-3-羧酸, 西普乐

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₇H₁₈FN₃O₃

化学文摘社编号:

85721-33-1

分子量:

331.34

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329830880

MDL number:

MFCD00185755

Beilstein/REAXYS Number:

3568352

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

ciprofloxacin

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OC(=O)C1=CN(C2CC2)c3cc(N4CCNCC4)c(F)cc3C1=O

InChI

1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)

InChI key

MYSWGUAQZAJSOK-UHFFFAOYSA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ciprofloxacin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 环丙沙星

存储类别

11 - Combustible Solids

wgk

WGK 2

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ciprofloxacin use in neonates: a systematic review of the literature.

Florentia Kaguelidou et al.

The Pediatric infectious disease journal, 30(2), e29-e37 (2010-11-05)

ciprofloxacin has no marketing authorization for use in neonates worldwide but it is prescribed for the treatment of neonatal life-threatening infections, mainly in developing countries and in Europe. Given the concerns about its toxicity in this population and the necessity

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

David J Serisier et al.

Thorax, 68(9), 812-817 (2013-05-18)

The delivery of antipseudomonal antibiotics by inhalation to Pseudomonas aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical extension of treatment strategies successfully developed in CF bronchiectasis. Dual release ciprofloxacin for inhalation (DRCFI) contains liposomal ciprofloxacin, formulated to optimise

Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study.

D Rodríguez-Pardo et al.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 20(11), O911-O919 (2014-04-29)

We aim to evaluate the epidemiology and outcome of gram-negative prosthetic joint infection (GN-PJI) treated with debridement, antibiotics and implant retention (DAIR), identify factors predictive of failure, and determine the impact of ciprofloxacin use on prognosis. We performed a retrospective

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0000198	04061837568022